Poorly controlled type II diabetes mellitus significantly enhances postoperative chemoresistance in patients with stage III colon cancer

Table 1 Comparison of the clinical and pathological characteristics between the non-diabetes mellitus and diabetes mellitus groups

Variables	Non-DM group (n = 160)	DM group (n = 118)	P value
Age (year, mean ± SD)	57.40 ± 8.31	62.69 ± 8.18	< 0.001a
Gender (male/female)	99/61	60/58	0.066
BMI > 24 kg/m2 (present/absent)	51/109	36/82	0.808
History of smoke (present/absent)	66/94	55/63	0.373
History of drinking (present/absent)	73/87	51/67	0.690
Hypertension (present/absent)	54/106	38/80	0.786
Cardiovascular disease (present/absent)	35/125	24/94	0.757
HbA1c (%, mean ± SD)	5.41 ± 0.33	6.57 ± 1.16	< 0.001a
FPG (mmol/L, mean ± SD)	4.85 ± 0.56	7.28 ± 2.92	< 0.001a
CEA (ng/mL, mean ± SD)	44.86 ± 155.54	52.90 ± 176.61	0.688
CA19-9 (ng/mL, mean ± SD)	172.39 ± 1118.65	118.72 ± 921.63	0.671
T stage (3/4)	122/38	82/36	0.208
N stage (1/2)	93/67	76/42	0.289
Tumor location (RCC/LCC)	62/98	49/69	0.640
Tumor size (cm, mean ± SD)	5.12 ± 2.05	4.67 ± 1.92	0.061
Vascular invasion (present/absent)	52/108	31/87	0.262
Perineural invasion (present/absent)	53/107	40/78	0.893
Tumor differentiation (MD/PD)	132/28	95/23	0.672

^aP < 0.05.

DM: Diabetes mellitus; BMI: Body mass index; HbA1c: Glycosylated hemoglobin; FPG: Fasting plasma glucose; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 199; LCC: Left-side colon cancer; RCC: Right-side colon cancer; MD: Moderately differentiated; PD: Poorly differentiated.